MHI-RJ-AVIATION-GROUP
20.7.2022 18:34:04 CEST | Business Wire | Press release
MHI RJ Aviation Group (MHIRJ) has announced today at the Farnborough Air Show the signing of an agreement with Air Nostrum Engineering and Maintenance (ANEM), appointing them as a MHIRJ Authorized Service Facility (ASF) in Europe. This agreement marks an important step in expanding MHIRJ’s service network internationally, allowing MHIRJ to extend, in collaboration with ANEM, the same levels of service that customers in North America receive through its wholly owned service centers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220720005641/en/
This agreement expands MHIRJ’s existing ASF support structure in Europe, introducing diversity and additional capacity to the existing network. ANEM’s addition will serve to meet the growing demands of the market, offering a wider array of availability and options for the European sector as well as for MHIRJ customers worldwide.
Based in Valencia (Spain), ANEM is part of the group of companies fully owned by the same shareholders of the airline Air Nostrum. ANEM currently serves as MRO and aircraft maintenance services provider for multiple airlines based in Europe, Africa, and Latin America. Air Nostrum has been operating CRJ Series aircraft since the year 1998 and currently operates the largest CRJ Series fleet in Europe, accounting for 37 CRJ Series aircraft. Air Nostrum is a ten-time MHIRJ Customer Reliability Award winner and a multiple time winner of the ERA Airline of the Year. Their vast operational experience will provide a first-rate base to support the CRJ Series fleet in Europe and across the world. Combining the strengths of ANEM and MHIRJ will bring forth our world-class Aftermarket network to the next level, providing our customers the full suite of MRO services.
Hiro Yamamoto, President and CEO of MHIRJ, commented “We are extremely proud to announce this agreement with Air Nostrum which will benefit customers in the European region, allowing them to access strong MRO support close to home. Reliability has always been the CRJ Series fleet’s strong suit; this agreement maintains that reliability and ensures an even stronger commitment to our customers.”
“ANEM brings a versatile set of capabilities that substantially enhances the CRJ Series MRO support for our European and International customers. As the maintenance arm of the largest CRJ Series carrier in Europe; our strategic collaboration with ANEM favorably positions us to collectively grow and expand support outside of North America,” commented Ismail Mokabel, Senior Vice-President and Head of Aftermarket at MHIRJ.
Amel Belkhamsa, Head of Aftermarket Commercial Services and Spare Parts Operations at MHIRJ, added “This is the first step in broadening our relationship with Air Nostrum to provide support to MHIRJ’s customers outside of North America. We wanted to find an MRO with a large range of capabilities to open the door to even more potential future collaboration, such as in the areas of material support and field response services, to ensure that all our international customers receive the best support available.”
Miguel Falcon, Vice Chairman of Air Nostrum and ANEM, said: “We are delighted to strengthen our cooperation with MHIRJ via this ASF agreement as its next Authorized MRO. We have 24 years of experience with the CRJ Series and have provided exceptional reliability for our customers, and this is due largely to the great relationship that we have with MHIRJ.”
Fermin Tirado, General Manager of ANEM, commented: “Thanks to the dedication and exceptional skills of our team members at ANEM, we´re quite pleased to sign this ASF agreement with MHIRJ that enhances our long-established partnership, allows us to increase the number of employees in ANEM, and grow our capacity for our airline customers.”
About Air Nostrum Group
Air Nostrum Group comprises different companies related to air transport and mobility including airlines, high speed railway transportation and firefighting, as well as related services companies: maintenance, training, flight support etc. The Group flagship, Air Nostrum Líneas Aereas, based in Spain, operates over 70,000 flights carrying more than 4,7 million passengers each year, being the leading regional aviation company in Spain and one of the largest in Europe. It operates for the Iberia Group under the Iberia Regional Air Nostrum brand, has sales over 500 million euros and employs more than 1,400 people.
About ANEM
ANEM is a PART 145 MRO (ES.145.060) and CAMO (ES.CAMO.059) company that arises from the split of AIR NOSTRUM’s business activities. ANEM performs the whole maintenance of the Air Nostrum’s Group fleets, including Air Nostrum, Hibernian, Melair, Paranair and PLYSA. These fleets are: CRJ200, CRJ900, CRJ1000, ATR72-600, and THRUSH S2R-T660. ANEM has a modern Hangar in Valencia Airport in order to cover all maintenance phases of the Air Nostrum’s Group and other operators’ fleets.
About MHI RJ Aviation Group
MHI RJ Aviation Group (MHIRJ) provides comprehensive critical operational, engineering and customer support solutions including maintenance, refurbishment, technical publications, marketing and sales activities for the global regional aircraft industry. Headquartered in Montréal, Canada, and bolstered by an Aerospace Engineering Centre, MHIRJ’s network of service centers, support offices and parts depots are positioned in important aviation hubs in Canada, the U.S. and Germany. A wholly owned subsidiary of Mitsubishi Heavy Industries, Ltd., MHI RJ Aviation Group includes MHI RJ Aviation ULC (Canada), MHI RJ Aviation Inc. (U.S.A.) and MHI RJ Aviation GmbH (Germany).
WE ARE HIRING. Visit mhirj.com/en/careers to know more.
For more information about MHI RJ Aviation Group, please visit: mhirj.com or follow our insights and stories on wingspan.mhirj.com
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, logistics & infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life, and ensure a safer world.
For more information, please visit www.mhi.com or follow our insights and stories on www.spectra.mhi.com
*CRJ, CRJ Series and MHIRJ are trademarks of MHI RJ Aviation ULC or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005641/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom